Regeneron Pharmaceuticals Inc
I · KI-Analyse
Kurzfassung
Regeneron discovers and commercializes medicines for eye diseases (EYLEA for macular degeneration), allergic conditions (Dupixent for eczema and asthma), cancer (Libtayo), and rare diseases [Yahoo Finance]. The company operates through a combination of selling FDA-approved drugs and investing heavily in research partnerships to develop next-generation treatments using technologies like gene-editing and radiopharmaceuticals [Yahoo Finance].
Regeneron Pharmaceuticals is a major biotechnology company that develops treatments for eye diseases, cancer, and rare conditions, generating $14,3B in annual revenue [Yahoo Finance]. The company recently suffered a significant setback when its experimental melanoma drug combination failed in late-stage testing, causing the stock to drop sharply [Yahoo Finance]. Despite this disappointment, Regeneron maintains a strong financial position with $4,1B in free cash flow and continues expanding through partnerships in gene-editing and oncology research [Yahoo Finance].
Regeneron is financially robust with exceptional profitability and zero net debt.
Sentinellis-Score
8,9/10
Finanziell gesund
Marktkapitalisierung
$66,1B
Umsatz (12 Monate)
$14,3B
Erklärt
Wie wir diese Zahlen lesen
Verständliche Leitfäden · ohne Konto
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
LesenPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
LesenAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
LesenII · Aktuelle Nachrichten
Was den Kurs bewegt hat
6 Meldungen · nach Relevanz sortiert
- Makro2026-05-20
Why Regeneron (REGN) Shares Are Trading Lower Today
Yahoo Finance
- Makro2026-05-19
Why Regeneron Pharmaceuticals (REGN) Is Down 11.7% After Key Melanoma Combo Trial Missed Its Goal
Yahoo Finance
- Makro2026-05-19
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
Yahoo Finance
- Makro2026-05-19
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B
Yahoo Finance
- Makro2026-05-19
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Melanoma Trial Setback And Share Price Pullback
Simply Wall St
- Makro2026-05-18
Regeneron's Late-Stage Melanoma Study Misses Primary Goal
Yahoo Finance
Premium · kostenlos mit jedem Konto
Pipeline concentration risk: The melanoma trial failure exposed Regeneron's dependence on successful late-stage trials to maintain growth, and further setbacks in other pipeline programs could significantly impact future revenue [Yahoo Finance]
Risiken
4
Chancen
5
Warnsignale
3
Führung
10
11 weitere Erkenntnisse im vollständigen Bericht — kostenlos mit jedem Konto.
Vollständige Regeneron Pharmaceuticals Inc-Analyse freischalten
Erstellen Sie ein kostenloses Konto für den vollständigen KI-Bericht mit Quellenangaben im Text.
- 4 Risiken, 5 Chancen und 3 Warnsignale — jeweils mit Quelle
- Über 100 Finanzkennzahlen mit Charts und Vergleichen
- Vollständige Nachrichten-Zusammenfassungen mit Quellenlinks
- Führungsteam und Vergütung
III · Ähnliche Unternehmen
Das könnte Sie auch interessieren
Gleicher Sektor · Gesundheitswesen — oder vergleichbare Finanzlage
Auf Ihre Watchlist setzen?